Register July 2016 No. 727
Chapter DCF 154
SUBSTANCE ABUSE SCREENING, TESTING, AND TREATMENT FOR THE
CHILDREN FIRST PROGRAM
DCF 154.03 Information about the requirement for controlled substance abuse screening, testing, and treatment.
DCF 154.04 Administering a controlled substance abuse screening questionnaire to determine reasonable suspicion of substance abuse.
DCF 154.05 Requiring a test for the use of a controlled substance.
DCF 154.06 Requiring participation in treatment.
DCF 154.07 Effect of completing, voluntarily withdrawing, or being terminated from a work experience program.
DCF 154.08 Confidentiality of records.
DCF 154.01
DCF 154.01
Purpose. The purpose of this chapter is to establish a process to screen for, and, if appropriate, test for the use of controlled substances by persons ordered to participate in the Children First work experience program administered by the department under s.
49.36, Stats., and to refer persons determined to be abusing a controlled substance to a treatment provider for a substance abuse assessment and evaluation and appropriate treatment as required by s.
49.162, Stats.
DCF 154.01 History
History: EmR1612: emerg. cr. eff. 3-17-16; CR 16-022: cr. Register July 2016 No. 727, eff. 8-1-16. DCF 154.02
DCF 154.02
Definitions. In this chapter:
DCF 154.02(2)
(2) “Confirmation test" means an analytical procedure used to quantify a specific controlled substance or its metabolite in a specimen through a test that is different in scientific principle from that of the initial test procedure and capable of providing requisite specificity, sensitivity, and quantitative accuracy to positively determine use of a controlled substance.
DCF 154.02(3)
(3) “Controlled substance" or “substance" has the meaning given for “controlled substance" in s.
961.01 (4), Stats.
DCF 154.02(4)
(4) “Department" means the department of children and families.
DCF 154.02(4m)
(4m) “Medical review officer" means a licensed physician employed by or providing services under contract to a drug testing vendor who has knowledge of substance abuse disorders and laboratory testing procedures and who has the necessary training and experience to interpret and evaluate a person's positive test result in relation to that person's medical history and current valid prescriptions.
DCF 154.02(5)
(5) “Metabolite" means a chemical present in the body when a controlled substance is being broken down through natural metabolic processes that can be detected or measured as a positive indicator that a controlled substance associated with the metabolite has been used.
DCF 154.02(7)
(7) “Person" means a parent who is not a custodial parent under s.
767.55 (2) (a), Stats., who has been ordered by the court pursuant to s.
767.55 (2) (am), Stats., to participate in a work experience and job training program under s.
49.36, Stats.
DCF 154.02(8)
(8) “Reasonable suspicion" means suspicion of controlled substance abuse by a person based on that person's score on a screening questionnaire.
DCF 154.02(9)
(9) “Screening" means completion of a questionnaire regarding the person's current and prior use of controlled substances.
DCF 154.02(10)
(10) “Specimen" means tissue, fluid, or a product of the human body capable of revealing the presence of controlled substances or their metabolites.
DCF 154.02(11)
(11) “Treatment" means services that are conducted under clinical supervision to assist a person through the process of recovery from controlled substance abuse and may include screening for abuse of controlled substances, application of approved placement criteria, intake, orientation, assessment, individualized treatment planning, intervention, individual or group and family counseling, referral, discharge planning, after care or continuing care, recordkeeping, consultation with other professionals regarding the patient's treatment, recovery and case management, crisis intervention, client education, employment, and problem resolution in life skills functioning.
DCF 154.02(12)
(12) “Treatment program" means a program certified to provide treatment for controlled substance abuse as a medically managed inpatient service under
s. DHS 75.10, a medically monitored treatment service under
s. DHS 75.11, a day treatment service under
s. DHS 75.12, an
outpatient treatment service under s. DHS 75.13, a transitional residential treatment service under
s. DHS 75.14, or a narcotic treatment service for opiate addiction under
s. DHS 75.15.
DCF 154.02(13)
(13) “Treatment provider" or “provider" means a provider of treatment for controlled substance abuse certified by the department of health services under the provisions of
ch. DHS 75.
DCF 154.02(14)
(14) “Work experience program" or “program" means a work experience program for noncustodial parents under s.
49.36, Stats.
DCF 154.02 History
History: EmR1612: emerg. cr. eff. 3-17-16; CR 16-022: cr. Register July 2016 No. 727, eff. 8-1-16; (6) renum. to (4m) under s. 13.92 (4) (b) 1., Stats., Register July 2016 No. 727. DCF 154.03
DCF 154.03
Information about the requirement for controlled substance abuse screening, testing, and treatment. An administering agency shall provide to any person who has been ordered by a court to register for a work experience program under s.
49.36, Stats., information that explains the requirement to undergo screening, testing, and treatment for abuse of controlled substances. The information shall be in a format approved by the department.
DCF 154.03 History
History: EmR1612: emerg. cr. eff. 3-17-16; CR 16-022: cr. Register July 2016 No. 727, eff. 8-1-16. DCF 154.04
DCF 154.04
Administering a controlled substance abuse screening questionnaire to determine reasonable suspicion of substance abuse. DCF 154.04(1)
(1)
Who must complete a screening questionnaire. An administering agency shall administer a controlled substance abuse screening questionnaire approved by the department to any person ordered to participate in a work experience program.
DCF 154.04(2)
(2) Effect of failing to complete screening questionnaire. The person is required to answer all questions on the screening questionnaire, sign and date the questionnaire, and submit it to the administering agency. A person who fails to submit a completed screening questionnaire is not eligible to participate in a work experience program, and the administering agency shall inform the clerk of courts by affidavit that the person is not eligible to participate in the program.
DCF 154.04(3)
(3) Effect of successfully passing the screening questionnaire. A person whose score on the screening questionnaire does not establish a reasonable suspicion of abuse of a controlled substance has fully satisfied the requirements of this chapter and may participate in a work experience program subject to this chapter without further screening, testing, or treatment.
DCF 154.04 History
History: EmR1612: emerg. cr. eff. 3-17-16; CR 16-022: cr. Register July 2016 No. 727, eff. 8-1-16. DCF 154.05
DCF 154.05
Requiring a test for the use of a controlled substance. DCF 154.05(1)(1)
Who may be required to undergo testing. A person whose score on the screening questionnaire establishes a reasonable suspicion of abuse of a controlled substance shall be required to undergo a test for the use of a controlled substance.
DCF 154.05(2)
(2) Nature of testing required. Testing shall consist of laboratory analysis of a specimen collected from a person by a drug testing vendor. The department shall provide to each administering agency a list of all controlled substances or metabolites of controlled substances that must be included in the test and cutoff levels for the test and cutoff levels for any confirmation test that may be used. The department may add or delete controlled substances or metabolites that must be included in the laboratory test to reflect changes in pre-employment drug testing practices of Wisconsin employers. Any positive test result on the initial drug test shall be confirmed through a confirmation test using the original specimen collected from the person.
DCF 154.05(3)
(3) Contract for testing services. Subject to the department's approval, the administering agency may contract with any qualified drug testing vendor to collect a specimen, carry out laboratory analysis of the specimen, store the specimen for confirmatory testing if required, complete confirmatory testing, and provide review by a medical review officer. The department may require the administering agency to use a specific testing service procured through state contracting if the department determines that volume discounts or other preferential pricing terms can be achieved through a statewide contract.
DCF 154.05 Note
The federal Centers for Medicare & Medicaid Services (CMS) regulates all laboratory testing (except research) performed on humans in the U.S. through the Clinical Laboratory Improvement Amendments (CLIA). Any entity or facility performing drug or alcohol testing or screening on specimens derived from the human body for the purpose of providing information for the diagnosis, prevention, or treatment of any disease or impairment of, or the assessment of the health of, human beings is considered a laboratory and must obtain an appropriate CLIA certificate and meet the applicable CLIA standards or cease testing.
DCF 154.05(4)
(4) Refusal to submit to a test. A person refuses to submit to a test if the person does any of the following:
DCF 154.05(4)(a)
(a) Fails or refuses to provide a specimen during an appointment scheduled by the administering agency for that purpose.
DCF 154.05(4)(b)
(b) Fails or refuses to appear for a test at the time and place directed by the administering agency.
DCF 154.05(4)(c)
(c) Fails or refuses to complete any form or release of information required for testing, including those required by the drug testing vendor that permit the drug testing vendor to report test results to the administering agency.
DCF 154.05(4)(e)
(e) Fails or refuses to provide verification of identity to the drug testing vendor.
DCF 154.05(4)(f)
(f) Fails or refuses to cooperate with the medical review officer, including refusal to complete an interview or answer questions or refusal to provide records necessary to demonstrate possession of a valid prescription.
DCF 154.05(5)
(5) Effect of refusal to submit to a test. A person who refuses to submit to a test under
sub. (4) is ineligible to participate in a work experience program until the person submits to a test. The administering agency may direct a person who has refused to submit to a test under
sub. (4) and subsequently agrees to submit to a test to undergo drug testing on a random basis at any time within 10 days after the person agrees to submit to a test. A person may not participate in the work experience program until the person undergoes a test for the use of a controlled substance and test results have been reported to the administering agency. If a person refuses to submit to a test for a period longer than 10 days, the administering agency shall inform the clerk of courts by affidavit that the person is not eligible to participate in the program until the person submits to a test.
DCF 154.05(6)
(6) Requirement for a confirmation test. If a person tests positive for the use of a controlled substance, the drug testing vendor shall perform a confirmation test using the same specimen obtained for the initial drug test. The results of the confirmation test shall be verified by a medical review officer after considering the person's medical history as well as any current valid prescription and use of over-the counter medication. All test results that are non-negative shall be interpreted as positive or negative by the drug testing vendor's medical review officer who shall be responsible for determining the presence of a controlled substance.
DCF 154.05(7)
(7) Accepting test results from another program. Results of a drug test performed by another state program, including a program under s.
49.159 (1) (b),
49.163,
49.45 (23) (g),
49.79 (9) (d), or
108.133, Stats., or a drug test carried out by the Wisconsin department of corrections, can be used by an administering agency to determine whether to refer a person to treatment if the prior test results are provided directly to the administering agency, all the controlled substances and metabolites required by the department to be tested under this chapter are included in the prior test results, and the test occurred within the previous 90 days.
DCF 154.05(8)
(8) Effect of a negative test. A person who undergoes a test for the use of a controlled substance under this section and tests negative for use of a controlled substance or tests positive for use of a controlled substance but provides evidence of a valid prescription for each controlled substance for which the person tests positive will have fully satisfied the requirements of this chapter and may participate in a work experience program without further screening, testing, or treatment.
DCF 154.05(9)
(9) Effect of a positive test. A person whose test results are positive for any controlled substance or metabolite tested and who fails to present evidence of a valid prescription for the controlled substance shall be required to participate in treatment under
s. DCF 154.06.
DCF 154.05 History
History: EmR1612: emerg. cr. eff. 3-17-16; CR 16-022: cr. Register July 2016 No. 727, eff. 8-1-16. DCF 154.06
DCF 154.06
Requiring participation in treatment. DCF 154.06(1)(1)
Who may be required to participate in treatment. Every person who undergoes a test under
s. DCF 154.05 and tests positive for the use of a controlled substance without presenting
evidence satisfactory to the administering agency that the individual possesses a valid prescription for each controlled substance for which the individual tests positive, and as determined by the medical review officer for the drug testing vendor, shall be required to participate in treatment in order to be eligible to participate in a work experience program.
DCF 154.06(2)
(2) Referral for treatment. The administering agency shall provide information to every person required to participate in treatment about treatment providers and county-specific assessment and enrollment activities required for entry into treatment. The administering agency shall monitor the person's progress in entering and completing treatment and the results of any random testing for the use of a controlled substance carried out during or at the conclusion of treatment.
